FARVATX: Family‐Based Rare Variant Association Test for X‐Linked Genes

Although the X chromosome has many genes that are functionally related to human diseases, the complicated biological properties of the X chromosome have prevented efficient genetic association analyses, and only a few significantly associated X‐linked variants have been reported for complex traits. For instance, dosage compensation of X‐linked genes is often achieved via the inactivation of one allele in each X‐linked variant in females; however, some X‐linked variants can escape this X chromosome inactivation. Efficient genetic analyses cannot be conducted without prior knowledge about the gene expression process of X‐linked variants, and misspecified information can lead to power loss. In this report, we propose new statistical methods for rare X‐linked variant genetic association analysis of dichotomous phenotypes with family‐based samples. The proposed methods are computationally efficient and can complete X‐linked analyses within a few hours. Simulation studies demonstrate the statistical efficiency of the proposed methods, which were then applied to rare‐variant association analysis of the X chromosome in chronic obstructive pulmonary disease. Some promising significant X‐linked genes were identified, illustrating the practical importance of the proposed methods.     

Kernel‐Machine Testing Coupled with a Rank‐Truncation Method for Genetic Pathway Analysis

Traditional genome‐wide association studies (GWASs) usually focus on single‐marker analysis, which only accesses marginal effects. Pathway analysis, on the other hand, considers biological pathway gene marker hierarchical structure and therefore provides additional insights into the genetic architecture underlining complex diseases. Recently, a number of methods for pathway analysis have been proposed to assess the significance of a biological pathway from a collection of single‐nucleotide polymorphisms. In this study, we propose a novel approach for pathway analysis that assesses the effects of genes using the sequence kernel association test and the effects of pathways using an extended adaptive rank truncated product statistic. It has been increasingly recognized that complex diseases are caused by both common and rare variants. We propose a new weighting scheme for genetic variants across the whole allelic frequency spectrum to be analyzed together without any form of frequency cutoff for defining rare variants. The proposed approach is flexible. It is applicable to both binary and continuous traits, and incorporating covariates is easy. Furthermore, it can be readily applied to GWAS data, exome‐sequencing data, and deep resequencing data. We evaluate the new approach on data simulated under comprehensive scenarios and show that it has the highest power in most of the scenarios while maintaining the correct type I error rate. We also apply our proposed methodology to data from a study of the association between bipolar disorder and candidate pathways from Wellcome Trust Case Control Consortium (WTCCC) to show its utility.     

Design of association studies with pooled or un‐pooled next‐generation sequencing data

Most common hereditary diseases in humans are complex and multifactorial. Large‐scale genome‐wide association studies based on SNP genotyping have only identified a small fraction of the heritable variation of these diseases. One explanation may be that many rare variants (a minor allele frequency, MAF <5%), which are not included in the common genotyping platforms, may contribute substantially to the genetic variation of these diseases. Next‐generation sequencing, which would allow the analysis of rare variants, is now becoming so cheap that it provides a viable alternative to SNP genotyping. In this paper, we present cost‐effective protocols for using next‐generation sequencing in association mapping studies based on pooled and un‐pooled samples, and identify optimal designs with respect to total number of individuals, number of individuals per pool, and the sequencing coverage. We perform a small empirical study to evaluate the pooling variance in a realistic setting where pooling is combined with exon‐capturing. To test for associations, we develop a likelihood ratio statistic that accounts for the high error rate of next‐generation sequencing data. We also perform extensive simulations to determine the power and accuracy of this method. Overall, our findings suggest that with a fixed cost, sequencing many individuals at a more shallow depth with larger pool size achieves higher power than sequencing a small number of individuals in higher depth with smaller pool size, even in the presence of high error rates. Our results provide guidelines for researchers who are developing association mapping studies based on next‐generation sequencing. Genet. Epidemiol. 34: 479–491, 2010. © 2010 Wiley‐Liss, Inc.     

Pathway‐Based Approaches for Sequencing‐Based Genome‐Wide Association Studies

For analyzing complex trait association with sequencing data, most current studies test aggregated effects of variants in a gene or genomic region. Although gene‐based tests have insufficient power even for moderately sized samples, pathway‐based analyses combine information across multiple genes in biological pathways and may offer additional insight. However, most existing pathway association methods are originally designed for genome‐wide association studies, and are not comprehensively evaluated for sequencing data. Moreover, region‐based rare variant association methods, although potentially applicable to pathway‐based analysis by extending their region definition to gene sets, have never been rigorously tested. In the context of exome‐based studies, we use simulated and real datasets to evaluate pathway‐based association tests. Our simulation strategy adopts a genome‐wide genetic model that distributes total genetic effects hierarchically into pathways, genes, and individual variants, allowing the evaluation of pathway‐based methods with realistic quantifiable assumptions on the underlying genetic architectures. The results show that, although no single pathway‐based association method offers superior performance in all simulated scenarios, a modification of Gene Set Enrichment Analysis approach using statistics from single‐marker tests without gene‐level collapsing (weighted Kolmogrov‐Smirnov [WKS]‐Variant method) is consistently powerful. Interestingly, directly applying rare variant association tests (e.g., sequence kernel association test) to pathway analysis offers a similar power, but its results are sensitive to assumptions of genetic architecture. We applied pathway association analysis to an exome‐sequencing data of the chronic obstructive pulmonary disease, and found that the WKS‐Variant method confirms associated genes previously published.     

Detecting association of rare and common variants based on cross‐validation prediction error

Despite the extensive discovery of disease‐associated common variants, much of the genetic contribution to complex traits remains unexplained. Rare variants may explain additional disease risk or trait variability. Although sequencing technology provides a supreme opportunity to investigate the roles of rare variants in complex diseases, detection of these variants in sequencing‐based association studies presents substantial challenges. In this article, we propose novel statistical tests to test the association between rare and common variants in a genomic region and a complex trait of interest based on cross‐validation prediction error (PE). We first propose a PE method based on Ridge regression. Based on PE, we also propose another two tests PE‐WS and PE‐TOW by testing a weighted combination of variants with two different weighting schemes. PE‐WS is the PE version of the test based on the weighted sum statistic (WS) and PE‐TOW is the PE version of the test based on the optimally weighted combination of variants (TOW). Using extensive simulation studies, we are able to show that (1) PE‐TOW and PE‐WS are consistently more powerful than TOW and WS, respectively, and (2) PE is the most powerful test when causal variants contain both common and rare variants.     

Regularized Rare Variant Enrichment Analysis for Case‐Control Exome Sequencing Data

Rare variants have recently garnered an immense amount of attention in genetic association analysis. However, unlike methods traditionally used for single marker analysis in GWAS, rare variant analysis often requires some method of aggregation, since single marker approaches are poorly powered for typical sequencing study sample sizes. Advancements in sequencing technologies have rendered next‐generation sequencing platforms a realistic alternative to traditional genotyping arrays. Exome sequencing in particular not only provides base‐level resolution of genetic coding regions, but also a natural paradigm for aggregation via genes and exons. Here, we propose the use of penalized regression in combination with variant aggregation measures to identify rare variant enrichment in exome sequencing data. In contrast to marginal gene‐level testing, we simultaneously evaluate the effects of rare variants in multiple genes, focusing on gene‐based least absolute shrinkage and selection operator (LASSO) and exon‐based sparse group LASSO models. By using gene membership as a grouping variable, the sparse group LASSO can be used as a gene‐centric analysis of rare variants while also providing a penalized approach toward identifying specific regions of interest. We apply extensive simulations to evaluate the performance of these approaches with respect to specificity and sensitivity, comparing these results to multiple competing marginal testing methods. Finally, we discuss our findings and outline future research.     

TARV: Tree‐based Analysis of Rare Variants Identifying Risk Modifying Variants in CTNNA2 and CNTNAP2 for Alcohol Addiction

Since the development of next generation sequencing (NGS) technology, researchers have been extending their efforts on genome‐wide association studies (GWAS) from common variants to rare variants to find the missing inheritance. Although various statistical methods have been proposed to analyze rare variants data, they generally face difficulties for complex disease models involving multiple genes. In this paper, we propose a tree‐based analysis of rare variants (TARV) that adopts a nonparametric disease model and is capable of exploring gene–gene interactions. We found that TARV outperforms the sequence kernel association test (SKAT) in most of our simulation scenarios, and by notable margins in some cases. By applying TARV to the study of addiction: genetics and environment (SAGE) data, we successfully detected gene CTNNA2 and its 43 specific variants that increase the risk of alcoholism in women, with an odds ratio (OR) of 1.94. This gene has not been detected in the SAGE data. Post hoc literature search also supports the role of CTNNA2 as a likely risk gene for alcohol addiction. In addition, we also detected a plausible protective gene CNTNAP2, whose 97 rare variants can reduce the risk of alcoholism in women, with an OR of 0.55. These findings suggest that TARV can be effective in dissecting genetic variants for complex diseases using rare variants data.     

A Fast and Noise‐Resilient Approach to Detect Rare‐Variant Associations With Deep Sequencing Data for Complex Disorders

Next generation sequencing technology has enabled the paradigm shift in genetic association studies from the common disease/common variant to common disease/rare‐variant hypothesis. Analyzing individual rare variants is known to be underpowered; therefore association methods have been developed that aggregate variants across a genetic region, which for exome sequencing is usually a gene. The foreseeable widespread use of whole genome sequencing poses new challenges in statistical analysis. It calls for new rare‐variant association methods that are statistically powerful, robust against high levels of noise due to inclusion of noncausal variants, and yet computationally efficient. We propose a simple and powerful statistic that combines the disease‐associated P‐values of individual variants using a weight that is the inverse of the expected standard deviation of the allele frequencies under the null. This approach, dubbed as Sigma‐P method, is extremely robust to the inclusion of a high proportion of noncausal variants and is also powerful when both detrimental and protective variants are present within a genetic region. The performance of the Sigma‐P method was tested using simulated data based on realistic population demographic and disease models and its power was compared to several previously published methods. The results demonstrate that this method generally outperforms other rare‐variant association methods over a wide range of models. Additionally, sequence data on the ANGPTL family of genes from the Dallas Heart Study were tested for associations with nine metabolic traits and both known and novel putative associations were uncovered using the Sigma‐P method.     

Genome‐Wide Association Analysis of Imputed Rare Variants: Application to Seven Common Complex Diseases

Genome‐wide association studies have been successful in identifying loci contributing effects to a range of complex human traits. The majority of reproducible associations within these loci are with common variants, each of modest effect, which together explain only a small proportion of heritability. It has been suggested that much of the unexplained genetic component of complex traits can thus be attributed to rare variation. However, genome‐wide association study genotyping chips have been designed primarily to capture common variation, and thus are underpowered to detect the effects of rare variants. Nevertheless, we demonstrate here, by simulation, that imputation from an existing scaffold of genome‐wide genotype data up to high‐density reference panels has the potential to identify rare variant associations with complex traits, without the need for costly re‐sequencing experiments. By application of this approach to genome‐wide association studies of seven common complex diseases, imputed up to publicly available reference panels, we identify genome‐wide significant evidence of rare variant association in PRDM10 with coronary artery disease and multiple genes in the major histocompatibility complex (MHC) with type 1 diabetes. The results of our analyses highlight that genome‐wide association studies have the potential to offer an exciting opportunity for gene discovery through association with rare variants, conceivably leading to substantial advancements in our understanding of the genetic architecture underlying complex human traits.     

How to Include Chromosome X in Your Genome‐Wide Association Study

In current genome‐wide association studies (GWAS), the analysis is usually focused on autosomal variants only, and the sex chromosomes are often neglected. Recently, a number of technical hurdles have been described that add to a reluctance of including chromosome X in a GWAS, including complications in genotype calling, imputation, and selection of test statistics. To overcome this, we provide a “how to” guide for analyzing X chromosomal data within a standard GWAS. Following a general pipeline for GWAS, we highlight the steps in which the X chromosome requires specific attention, and we give tentative advice for each of these. Through this, we show that by selection of sensible algorithms and parameter settings, the inclusion of chromosome X in GWAS is manageable. Closing this gap is expected to further elucidate the genetic background of complex diseases, especially of those with sex‐specific features.     

Detecting rare variants for complex traits using family and unrelated data

Large genome‐wide association studies (GWAS) have been performed to detect common genetic variants involved in common diseases, but most of the variants found this way account for only a small portion of the trait variance. Furthermore, candidate gene‐based resequencing suggests that many rare genetic variants contribute to the trait variance of common diseases. Here we propose two designs, sibpair and unrelated‐case designs, to detect rare genetic variants in either a candidate gene‐based or genome‐wide association analysis. First we show that we can detect and classify together rare risk haplotypes using a relatively small sample with either of these designs, and then have increased power to test association in a larger case‐control sample. This method can also be applied to resequencing data. Next we apply the method to the Wellcome Trust Case Control Consortium (WTCCC) coronary artery disease (CAD) and hypertension (HT) data, the latter being the only trait for which no genome‐wide association evidence was reported in the original WTCCC study, and identify one interesting gene associated with HT and four associated with CAD at a genome‐wide significance level of 5%. These results suggest that searching for rare genetic variants is feasible and can be fruitful in current GWAS, candidate gene studies or resequencing studies. Genet. Epidemiol. 34: 171–187, 2010. © 2009 Wiley‐Liss, Inc.     

A Robust Method for Genome‐Wide Association Meta‐Analysis With the Application to Circulating Insulin‐Like Growth Factor I Concentrations

Genome‐wide association studies (GWAS) offer an excellent opportunity to identify the genetic variants underlying complex human diseases. Successful utilization of this approach requires a large sample size to identify single nucleotide polymorphisms (SNPs) with subtle effects. Meta‐analysis is a cost‐efficient means to achieve large sample size by combining data from multiple independent GWAS; however, results from studies performed on different populations can be variable due to various reasons, including varied linkage equilibrium structures as well as gene‐gene and gene‐environment interactions. Nevertheless, one should expect effects of the SNP are more similar between similar populations than those between populations with quite different genetic and environmental backgrounds. Prior information on populations of GWAS is often not considered in current meta‐analysis methods, rendering such analyses less optimal for the detecting association. This article describes a test that improves meta‐analysis to incorporate variable heterogeneity among populations. The proposed method is remarkably simple in computation and hence can be performed in a rapid fashion in the setting of GWAS. Simulation results demonstrate the validity and higher power of the proposed method over conventional methods in the presence of heterogeneity. As a demonstration, we applied the test to real GWAS data to identify SNPs associated with circulating insulin‐like growth factor I concentrations.     

Meta‐Analysis of Sequencing Studies With Heterogeneous Genetic Associations

Recent advances in sequencing technologies have made it possible to explore the influence of rare variants on complex diseases and traits. Meta‐analysis is essential to this exploration because large sample sizes are required to detect rare variants. Several methods are available to conduct meta‐analysis for rare variants under fixed‐effects models, which assume that the genetic effects are the same across all studies. In practice, genetic associations are likely to be heterogeneous among studies because of differences in population composition, environmental factors, phenotype and genotype measurements, or analysis method. We propose random‐effects models which allow the genetic effects to vary among studies and develop the corresponding meta‐analysis methods for gene‐level association tests. Our methods take score statistics, rather than individual participant data, as input and thus can accommodate any study designs and any phenotypes. We produce the random‐effects versions of all commonly used gene‐level association tests, including burden, variable threshold, and variance‐component tests. We demonstrate through extensive simulation studies that our random‐effects tests are substantially more powerful than the fixed‐effects tests in the presence of moderate and high between‐study heterogeneity and achieve similar power to the latter when the heterogeneity is low. The usefulness of the proposed methods is further illustrated with data from National Heart, Lung, and Blood Institute Exome Sequencing Project (NHLBI ESP). The relevant software is freely available.     

Resequencing of pooled DNA for detecting disease associations with rare variants

A combination of common and rare variants is thought to contribute to genetic susceptibility to complex diseases. Recently, next‐generation sequencers have greatly lowered sequencing costs, providing an opportunity to identify rare disease variants in large genetic epidemiology studies. At present, it is still expensive and time consuming to resequence large number of individual genomes. However, given that next‐generation sequencing technology can provide accurate estimates of allele frequencies from pooled DNA samples, it is possible to detect associations of rare variants using pooled DNA sequencing. Current statistical approaches to the analysis of associations with rare variants are not designed for use with pooled next‐generation sequencing data. Hence, they may not be optimal in terms of both validity and power. Therefore, we propose here a new statistical procedure to analyze the output of pooled sequencing data. The test statistic can be computed rapidly, making it feasible to test the association of a large number of variants with disease. By simulation, we compare this approach to Fisher's exact test based either on pooled or individual genotypic data. Our results demonstrate that the proposed method provides good control of the Type I error rate, while yielding substantially higher power than Fisher's exact test using pooled genotypic data for testing rare variants, and has similar or higher power than that of Fisher's exact test using individual genotypic data. Our results also provide guidelines on how various parameters of the pooled sequencing design affect the efficiency of detecting associations. Genet. Epidemiol. 34: 492–501, 2010. © 2010 Wiley‐Liss, Inc.     

An evaluation of statistical approaches to rare variant analysis in genetic association studies

Genome‐wide association (GWA) studies have proved to be extremely successful in identifying novel common polymorphisms contributing effects to the genetic component underlying complex traits. Nevertheless, one source of, as yet, undiscovered genetic determinants of complex traits are those mediated through the effects of rare variants. With the increasing availability of large‐scale re‐sequencing data for rare variant discovery, we have developed a novel statistical method for the detection of complex trait associations with these loci, based on searching for accumulations of minor alleles within the same functional unit. We have undertaken simulations to evaluate strategies for the identification of rare variant associations in population‐based genetic studies when data are available from re‐sequencing discovery efforts or from commercially available GWA chips. Our results demonstrate that methods based on accumulations of rare variants discovered through re‐sequencing offer substantially greater power than conventional analysis of GWA data, and thus provide an exciting opportunity for future discovery of genetic determinants of complex traits. Genet. Epidemiol. 34: 188–193, 2010. © 2009 Wiley‐Liss, Inc.     

Testing cross‐phenotype effects of rare variants in longitudinal studies of complex traits

Many gene mapping studies of complex traits have identified genes or variants that influence multiple phenotypes. With the advent of next‐generation sequencing technology, there has been substantial interest in identifying rare variants in genes that possess cross‐phenotype effects. In the presence of such effects, modeling both the phenotypes and rare variants collectively using multivariate models can achieve higher statistical power compared to univariate methods that either model each phenotype separately or perform separate tests for each variant. Several studies collect phenotypic data over time and using such longitudinal data can further increase the power to detect genetic associations. Although rare‐variant approaches exist for testing cross‐phenotype effects at a single time point, there is no analogous method for performing such analyses using longitudinal outcomes. In order to fill this important gap, we propose an extension of Gene Association with Multiple Traits (GAMuT) test, a method for cross‐phenotype analysis of rare variants using a framework based on the distance covariance. The approach allows for both binary and continuous phenotypes and can also adjust for covariates. Our simple adjustment to the GAMuT test allows it to handle longitudinal data and to gain power by exploiting temporal correlation. The approach is computationally efficient and applicable on a genome‐wide scale due to the use of a closed‐form test whose significance can be evaluated analytically. We use simulated data to demonstrate that our method has favorable power over competing approaches and also apply our approach to exome chip data from the Genetic Epidemiology Network of Arteriopathy.     

Is It Rare or Common?

Many genome‐wide association studies (GWAS) have signals with unknown etiology. This paper addresses the question—is such an association signal caused by rare or common variants that lead to increased disease risk? For a genomic region implicated by a GWAS, we use single nucleotide polymorphism (SNP) data in a case‐control setting to predict how many common or rare variants there are, using a Bayesian analysis. Our objective is to compute posterior probabilities for configurations of rare and/or common variants. We use an extension of coalescent trees—the ancestral recombination graphs—to model the genealogical history of the samples based on marker data. As we expect SNPs to be in linkage disequilibrium with common disease variants, we can expect the trees to reflect the type of variants. To demonstrate the application, we apply our method to candidate gene sequencing data from a German case‐control study on nonsyndromic cleft lip with or without cleft palate. Genet. Epidemiol. 36:419‐429, 2012. © 2012 Wiley Periodicals, Inc.     

A Note on the Efficiencies of Sampling Strategies in Two‐Stage Bayesian Regional Fine Mapping of a Quantitative Trait

In focused studies designed to follow up associations detected in a genome‐wide association study (GWAS), investigators can proceed to fine‐map a genomic region by targeted sequencing or dense genotyping of all variants in the region, aiming to identify a functional sequence variant. For the analysis of a quantitative trait, we consider a Bayesian approach to fine‐mapping study design that incorporates stratification according to a promising GWAS tag SNP in the same region. Improved cost‐efficiency can be achieved when the fine‐mapping phase incorporates a two‐stage design, with identification of a smaller set of more promising variants in a subsample taken in stage 1, followed by their evaluation in an independent stage 2 subsample. To avoid the potential negative impact of genetic model misspecification on inference we incorporate genetic model selection based on posterior probabilities for each competing model. Our simulation study shows that, compared to simple random sampling that ignores genetic information from GWAS, tag‐SNP‐based stratified sample allocation methods reduce the number of variants continuing to stage 2 and are more likely to promote the functional sequence variant into confirmation studies.     

Rare variant association test with multiple phenotypes

Although genome‐wide association studies (GWAS) have now discovered thousands of genetic variants associated with common traits, such variants cannot explain the large degree of “missing heritability,” likely due to rare variants. The advent of next generation sequencing technology has allowed rare variant detection and association with common traits, often by investigating specific genomic regions for rare variant effects on a trait. Although multiple correlated phenotypes are often concurrently observed in GWAS, most studies analyze only single phenotypes, which may lessen statistical power. To increase power, multivariate analyses, which consider correlations between multiple phenotypes, can be used. However, few existing multivariant analyses can identify rare variants for assessing multiple phenotypes. Here, we propose Multivariate Association Analysis using Score Statistics (MAAUSS), to identify rare variants associated with multiple phenotypes, based on the widely used sequence kernel association test (SKAT) for a single phenotype. We applied MAAUSS to whole exome sequencing (WES) data from a Korean population of 1,058 subjects to discover genes associated with multiple traits of liver function. We then assessed validation of those genes by a replication study, using an independent dataset of 3,445 individuals. Notably, we detected the gene ZNF620 among five significant genes. We then performed a simulation study to compare MAAUSS's performance with existing methods. Overall, MAAUSS successfully conserved type 1 error rates and in many cases had a higher power than the existing methods. This study illustrates a feasible and straightforward approach for identifying rare variants correlated with multiple phenotypes, with likely relevance to missing heritability.     

Gene‐based segregation method for identifying rare variants in family‐based sequencing studies

Whole‐exome sequencing using family data has identified rare coding variants in Mendelian diseases or complex diseases with Mendelian subtypes, using filters based on variant novelty, functionality, and segregation with the phenotype within families. However, formal statistical approaches are limited. We propose a gene‐based segregation test (GESE) that quantifies the uncertainty of the filtering approach. It is constructed using the probability of segregation events under the null hypothesis of Mendelian transmission. This test takes into account different degrees of relatedness in families, the number of functional rare variants in the gene, and their minor allele frequencies in the corresponding population. In addition, a weighted version of this test allows incorporating additional subject phenotypes to improve statistical power. We show via simulations that the GESE and weighted GESE tests maintain appropriate type I error rate, and have greater power than several commonly used region‐based methods. We apply our method to whole‐exome sequencing data from 49 extended pedigrees with severe, early‐onset chronic obstructive pulmonary disease (COPD) in the Boston Early‐Onset COPD study (BEOCOPD) and identify several promising candidate genes. Our proposed methods show great potential for identifying rare coding variants of large effect and high penetrance for family‐based sequencing data. The proposed tests are implemented in an R package that is available on CRAN ( https://cran.r-project.org/web/packages/GESE/ ).